InvestorsHub Logo
Followers 145
Posts 27558
Boards Moderated 3
Alias Born 02/07/2004

Re: None

Saturday, 10/21/2017 9:01:21 AM

Saturday, October 21, 2017 9:01:21 AM

Post# of 3872
RedHill Biopharma up 10% premarket following U.S. Orphan Drug tag for upamostat

Oct. 20, 2017 7:42 AM ET|By: Douglas W. House, SA News Editor
RedHill Biopharma (NASDAQ:RDHL) is up 10% premarket on light volume. Yesterday, the FDA designed MESUPRON (upamostat) an Orphan Drug for the treatment of pancreatic cancer.

Previously: RedHill's upamostat an Orphan Drug in U.S. for pancreatic cancer (Oct. 19)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News